RecruitingPhase 2NCT06655896

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals
Novartis Pharmaceuticals
Intervention: rapcabtagene autoleucel(biological)
Enrollment: 96 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2024 – 2032

Study locations (30)

UCLA, Los Angeles, California, United States
UCSF, San Francisco, California, United States
Sutter Health Network, San Pablo, California, United States
FL Medical Clinic Orlando Health, Zephyrhills, Florida, United States
Northwestern University, Chicago, Illinois, United States
University Of Iowa, Iowa City, Iowa, United States
Boston Medical Center, Boston, Massachusetts, United States
Michigan Med University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
James Cancer Hospital, Columbus, Ohio, United States
Oregon Health Sciences University, Portland, Oregon, United States
Avera Cancer, Sioux Falls, South Dakota, United States
LDS Hospital, Salt Lake City, Utah, United States
Novartis Investigative Site, Camperdown, New South Wales, Australia
Novartis Investigative Site, Darlinghurst, New South Wales, Australia
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06655896 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials